Karyopharm Therapeutics Inc., is a clinical-stage pharmaceutical company focused on the discovery, development and subsequent commercialization of novel, first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. The company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. Karyopharm's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications.
| Website: | www.karyopharm.com |
| Email: | ikarp@karyopharm.com |
| Main Phone: | +1 617 658-0600 |
| Address: | 85 Wells Avenue |
| Address 2: | 2nd Floor |
| State: | MA |
| City / Town: | Newton |
| Country: | USA |
| Postal Code: | 02459 |
| Exchange: | NGS |
| CEO: | Michael G. Kauffman |
| Employees: | 154 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 10.01 | Change $ -0.18 | Change % -1.77 | Tick N/A |
| Bid 9.90 | Bid Size 1,000.00 | Ask 10.29 | Ask Size 200.00 |
| Open 10.14 | High 10.30 | Low 9.76 | Prev Close 10.19 |
| Last Trade | Volume 685,845 | 52 Wk Hi 21.71 | 52 Wk Low 9.00 |
| Market Cap 607.7 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 60,707,876.00 | EPS (TTM) -2.98 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 30 | 88 |
| Number of Buys | 16 | 41 |
| Number of Sells | 14 | 47 |
| Net Activity | -2000 | -2763 |
| Last 10 Buys | Shares |
|---|---|
| Ran Frenkel | 1,000 |
| Ran Frenkel | 1,000 |
| Justin A. Renz | 1,000 |
| Barry E. Greene | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Michael G. Kauffman | 1,000 |
| Sharon Shacham | 1,000 |
| Sharon Shacham | 1,000 |
| Michael G. Kauffman | 1,000 |
| Christopher Brett Primiano | 1,000 |
| Mansoor Raza Mirza | 1,000 |
| Michael G. Kauffman | 1,000 |
| Sharon Shacham | 1,000 |
| Sharon Shacham | 1,000 |
| Michael G. Kauffman | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 30 | 30 | 30 | 30 |
| Low Target Price Estimate | 14 | 14 | 14 | 14 |
| Mean Target Price Estimate | 22 | 22 | 22.1 | 22 |
| Standard Deviation | 5.16 | 5.16 | 5.11 | 5.16 |
| Date of Most Recent Estimate | 06/02/18 | 05/24/18 | 05/22/18 | 06/02/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| CT ORDER | 1 | 2018-06-14 | |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 8-K | Report of unscheduled material events or corporate changes. | 32 | 2018-06-07 |
| 8-K | Report of unscheduled material events or corporate changes. | 9 | 2018-05-24 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-10 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 194 | 2018-05-10 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 |
| Moderate Sell | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.6 | 1.4 | 1.4 | 1.4 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
